Cargando…
Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
BACKGROUND: Introduction of calcineurin inhibitors had led to improved survival rates in liver transplant recipients. However, long-term use of calcineurin inhibitors is associated with a higher risk of chronic renal failure, neurotoxicity, de novo malignancies, recurrence of hepatitis C viral (HCV)...
Autores principales: | Nashan, Bjorn, Schemmer, Peter, Braun, Felix, Dworak, Markus, Wimmer, Peter, Schlitt, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384314/ https://www.ncbi.nlm.nih.gov/pubmed/25873064 http://dx.doi.org/10.1186/s13063-015-0626-0 |
Ejemplares similares
-
Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial
por: Nashan, Björn, et al.
Publicado: (2021) -
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma
por: Sapisochin, Gonzalo, et al.
Publicado: (2022) -
Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation
por: Chapman, William C., et al.
Publicado: (2017) -
Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
por: De Simone, P, et al.
Publicado: (2012) -
Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study
por: Watarai, Yoshihiko, et al.
Publicado: (2021)